How to Buy Illumina Stock
Illumina Inc
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
Illumina stock last closed at $134.87, down 1.15% from the previous day, and has decreased 7.89% in one year. It has underperformed other stocks in the Diagnostics & Research industry by 0.21 percentage points. Illumina stock is currently +96.32% from its 52-week low of $68.70, and -11.88% from its 52-week high of $153.06.
At the moment, there are 152.8M shares of ILMN outstanding. The market capitalization of ILMN is $20.61B. In the past 24 hours, 1.7M ILMN shares were traded.
How to Buy Illumina Stock
Not sure how to invest in Illumina stock? Here's how.
- Choose where to buy Illumina stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you decide where to buy Illumina stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Put funds into your investment account: Choose your method of payment and add your information.
- Research Illumina stock: The Illumina ticker symbol is ILMN. Is Illumina stock a good investment? Should you buy shares of ILMN? How do ILMN's underlying business fundamentals look? Do top analysts think Illumina is a good buy? Why has ILMN's stock price moved recently? (Hint: Our stock analysis website can help you understand if ILMN is a good stock to buy).
- Make your ILMN buy order: Decide if you will purchase ILMN shares at the current market price or use a limit order to purchase ILMN shares at a given price.
- Monitor your ILMN position: Create a watchlist to get the latest news on your new investment in Illumina stock.
Step 1: Choose where to buy Illumina stock
You need a brokerage account to access the NASDAQ market and buy ILMN stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world markets: From Tech to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal details so you can invest in ILMN today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to start a new trading account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've filled out your info on the best investment app, you can securely and quickly fund your account:
Watch this video walkthrough if you need help transferring money into your new investment account.
Step 4: Research Illumina stock
After you have chosen the best place to buy Illumina stock, it's critical to evaluate their stock before you invest, so you can comprehend the risk and opportunity.
Illumina shares data
Illumina Due Diligence Score
WallStreetZen was designed to help everyday investors perform more accurate fundamental analysis in less time.
You can view all of the due diligence checks on ILMN's stock page.
Is ILMN stock overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge ILMN's true value.
Using relative valuations metrics:
- ILMN could be overvalued based on its P/E ratio of 30.17x, relative to Diagnostics & Research industry P/E ratio of 22.53x
- ILMN could be overvalued based on its P/B ratio of 8.66x, relative to Diagnostics & Research industry P/B ratio of 4.45x
- ILMN may be overvalued based on its PEG ratio of 3.35x
You can access more valuation analysis on ILMN's stock here.
ILMN Financials at a glance
Pros:
- ILMN earnings of $995.00M is not sufficient to cover its interest payments.
- There are more short-term assets than long-term liabilities on the ILMN balance sheet.
- ILMN profit margin has gone up from -36.1% to 16.4% in the past year.
- ILMN's operating cash flow of $1.12B allows it to safely service it's debt of $2.50B.
- There are more short-term assets than short-term liabilities on the ILMN balance sheet.
Cons:
- ILMN has a relatively high debt to equity ratio of 1.59.
- Total ILMN debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Illumina stock, according to analysts?
Out of 11 Wall Street analysts who give forecasts on ILMN, the consensus analyst rating on ILMN is a Hold
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent ILMN Analyst Recommendations
Vijay Kumar, a bottom 16% analyst from Evercore ISI Group maintains ILMN with a buy rating and raises their ILMN price target from $132.00 to $142.00, on Oct 31, 2025.
Tejas Savant, a bottom 11% analyst from Morgan Stanley maintains ILMN with a hold rating and raises their ILMN price target from $100.00 to $105.00, on Aug 4, 2025.
Morgan Stanley's Tejas Savant raised their price target on Illumina (NASDAQ: ILMN) by 5% from $100 to $105 on 2025/08/04. The analyst maintained their Hold rating on the stock.
Illumina reported its Q2 2025 earnings.
Savant attributed the quarter's beat to "strong margins."
Looking ahead, Illumina's clinical adoption momentum is encouraging.
However, Savant added that the company's research end market remained subdued in the quarter because of budget constraints.
Earnings Report
For Q2 2025, Illumina reported:
- EPS of $1.19, which beat the Zacks Consensus Estimate of $1.02 and, by 230.6%, Q2 2024’s $0.36.
- Revenue of $1.06B, which beat the Zacks Consensus Estimate by 1.11% and, by 3%, Q2 2024’s $1.11B.
For FY 2025, management guided:
- EPS of $4.45 to $4.55.
- Revenue to decline by 0.5% to 2.5%.
CEO Jacob Thaysen commented: “The Illumina team again delivered results that exceeded our guidance, driven by the continued ramp in X consumables, as well as accelerating growth in clinical, our largest customer segment.
“In research, we are actively helping our customers navigate a constrained funding environment.
“Even in these challenging conditions, the team’s focus on operational excellence helped drive margin expansion, enabling us to increase our expectations for the year.”
Conor McNamara, a bottom 2% analyst from RBC Capital maintains ILMN with a buy rating and raises their ILMN price target from $118.00 to $126.00, on Aug 1, 2025.
Catherine Ramsey, a top 22% analyst from Baird maintains ILMN with a hold rating and raises their ILMN price target from $84.00 to $105.00, on Jul 28, 2025.
Sung Ji Nam, a top 40% analyst from ScotiaBank downgrades ILMN to a hold rating and announces their ILMN price target of $125.00, on Jul 11, 2025.
You can dig deeper into what analysts are forecasting on the Illumina stock forecast page.
Metrics for Advanced ILMN Traders
ILMN Earnings
Last year, ILMN earnings were $703.00M. Over the past 5 year, ILMN's earnings have increased by 0.59% per year. This was slower than the Diagnostics & Research industry average of 7.78%.
Last year, ILMN revenue was $4.29B. In the past five year, ILMN's revenue has grown by 5.78% per year. This was slower than the Diagnostics & Research industry average of 9.37%.
Find out more about ILMN's earnings and revenue performance here.
What are ILMN executives and large shareholders up to?
In the last year, insiders at ILMN have sold more shares than they have bought.
Christensen Jakob Wedel, SVP StrategyCorp Development of ILMN, was the latest ILMN insider to sell. They sold $70,969.23 worth of ILMN shares on Dec 8, 2025.
Research more about who owns ILMN stock here.
Does ILMN stock generate passive income?
No, Illumina doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your ILMN buy order
There are two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, place a limit order.
Press the Open button and your broker will execute the order.
If you require additional help buying stocks on eToro, click the helpful video below:
Step 6: Monitor your ILMN position
Now that you own some ILMN shares, you'll want to stay up-to-date on your stock purchase.
Make a watchlist to get alerted to the latest events about your ILMN stock.
ILMN Feed
How to Buy Stock in Illumina
To summarize, here are the 6 steps to buy Illumina stock:
- Choose where to buy Illumina stock
- Sign up for your brokerage account
- Put funds into your investment account
- Research Illumina stock
- Make your ILMN buy order
- Monitor your ILMN position
If you are looking for a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to watch your investment in Illumina, click below.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.